SCHEMBL2630746

SCHEMBL2630746

Clc1ncccc1C1=CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 4/20 0.41
PIK3CD O00329 3/20 0.40
PIK3CA P42336 3/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
BACE1 P56817 3/20 0.38
MAPK14 Q16539 2/20 0.37
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
CDC7 O00311 1/20 0.36
CDK2 P24941 1/20 0.36
CSNK1D P48730 1/20 0.36
CSNK1E P49674 1/20 0.36
CTSD P07339 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457269 0.81 BACE1 (0.49) PDE10APIK3CDPIK3CABACE1MAPK14
SCHEMBL2250102 0.81 BACE1 (0.42) PDE10APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2457641 0.74 PIK3CA (0.41) PDE10APIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2461569 0.72 BACE1 (0.43) PDE10APIK3CDPIK3CABACE1MAPK14
SCHEMBL23536642 0.72 PIM1 (0.42) PDE10APIK3CDPIK3CABACE1MAPK14
SCHEMBL2630914 0.71 PDE10A (0.47) PDE10AMAPK14PDCD1CD274CSNK1D
SCHEMBL3325941 0.71 BACE1 (0.43) PDE10APIK3CDPIK3CABACE1MAPK14
Hydrochloric Acid SCHEMBL2631179 0.71 PDE10A (0.47) PDE10AMAPK14PDCD1CD274CSNK1D
SCHEMBL2711567 0.71 PIK3CA (0.40) PDE10APIK3CDPIK3CABACE1MAPK14
SCHEMBL17874622 0.69 NMT1 (0.47) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9376450-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2016-06-28 US disclosed
US-9376450-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2016-06-28 US disclosed
US-9376450-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2016-06-28 US disclosed
US-20130253186-A1 HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS AMGEN INC. (US) 2013-09-26 US disclosed
US-8497265-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2013-07-30 US disclosed
US-8497265-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2013-07-30 US disclosed
US-8497265-B2 Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors AMGEN INC. (US) 2013-07-30 US disclosed
EP-2569302-A1 HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS Amgen, Inc (US) 2013-03-20 EP disclosed
WO-2011143495-A1 HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS AMGEN INC. (US) 2011-11-17 WO disclosed
WO-2011143495-A1 HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS AMGEN INC. (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130253186-A1 HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS PDE10A, PDE9A, PDE7A PDE10A 1/4885PIK3CD 101/4885PIK3CA 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.